Background: Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is a debilitating multisystem condition affecting more than 1 million adults in the United States.
M
yalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is a debilitating multisystem condition characterized by chronic and disabling fatigue and several other symptoms, including pain, sleep disturbance, neurologic and cognitive changes, motor impairment, and altered immune and autonomic responses (1) (2) (3) . Experts consider postexertional malaise and memory or concentration problems to be critical components (4 -6) , and several diagnostic criteria, including those released by the Institute of Medicine in 2015, require the presence of postexertional malaise (1, 2, (7) (8) (9) .
There is uncertainty regarding the cause of ME/ CFS, whether it is a pathologically discrete syndrome (2, 4) , whether ME should be considered a subset of CFS or its own distinct disease (6) , and whether symptoms are nonspecific and shared by other disease entities. Some propose that an inciting event initiates an immune response that leads to immune and neuroendocrine dysregulation (10, 11) . Viral causes have been studied on the basis of the observation that most patients report a sudden onset of symptoms that were preceded by a febrile illness with enlarged lymph nodes. However, no specific virus or other infectious agent has been identified, and not all patients experience a preceding febrile illness (10) .
The Centers for Disease Control and Prevention (CDC) reported a 0.3% prevalence of ME/CFS in the United States in 1997, corresponding to more than 1 million adults (12) . Through use of different case definitions or different diagnostic methods, the rate may be as high as 3.3% (13, 14) .
Given the multitude of symptoms that patients with ME/CFS experience, treatment approaches have been broad, including immunologic, pharmacologic, and behavioral treatments and complementary and alternative medicine. No medications for the treatment of ME/CFS have been approved by the U.S Food and Drug Administration (FDA); however, many have been used without review and approval (off-label), and some are not approved for any indication in the United States (for example, isoprinosine and rintatolimod). In an FDA survey, patients with ME/CFS identified treatments that fell into 2 broad categories: those intended to treat the cause of the disease and those targeting specific symptoms or perpetuating factors (15). Medications to treat causes include immune modulators, antivirals, and antibiotics. Interventions targeting symptoms include medications to treat specific symptoms, such as pain, fatigue, autonomic dysfunction, and sleep dysfunction, and nondrug therapies, such as yoga, exercise techniques, counseling, pacing strategies, and mental exercises (15). In practice, the clinical management of patients varies widely, and many patients receive a multifaceted approach to treatment.
This systematic review is part of a larger report to inform a research agenda for the National Institutes of Health (NIH) 2014 Pathways to Prevention Workshop, an evidence-based methodology workshop (16) . This review evaluates and summarizes research on the benefits and harms of medical and nonmedical treatments for ME/CFS based on trials enrolling patients meeting criteria for ME, CFS, or both and identifies limitations of current studies and needs for future research in this area.
METHODS
Key questions guiding this review were developed in collaboration with the NIH ME/CFS Working Group following a standard protocol, including input from key informants and a technical expert panel, registration in the PROSPERO database for systematic reviews (17) , and posting on an Agency for Healthcare Research and Quality (AHRQ) public Web site. Key questions concern the benefits and harms of therapeutic interventions for adults with ME/CFS, how interventions vary by patient subgroups, and characteristics of patients who respond and do not respond to interventions. A technical report details the methods and includes the analytic framework, search strategies, and additional evidence tables (16) .
Data Sources and Searches
A research librarian searched the following electronic databases to identify relevant articles published between January 1988 (year of first case definition) and September 2014: MEDLINE (Ovid), PsycINFO, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, and National Health Sciences Economic Evaluation Database. Searches were supplemented by references identified from additional sources, including trial registries, scientific information packets from manufacturers, reference lists, and experts.
Study Selection
We included English-language trials that enrolled patients aged 18 years or older who met the criteria for ME, CFS, or both according to at least 1 established case definition. Included were randomized, controlled trials of at least 12 weeks' duration that compared medications, complementary and alternative medicine approaches, counseling and behavior therapies, and exercise therapies with no treatment or other types of treatment. For completeness, we separately summarized additional trials of medications that were designed for shorter durations of treatment. Treatment outcomes were patient centered and included function, fatigue, quality of life, involvement in daily activities, and harms. We did not include studies of the results of laboratory tests or studies focusing on individual symptoms, such as pain.
Two investigators independently evaluated each study to determine inclusion eligibility. Disagreement was resolved by consensus, with a third investigator making the final decision as needed.
Data Extraction and Quality Assessment
From the included studies, one investigator extracted study details and a second investigator reviewed them for accuracy and completeness. Investigators rated the quality (risk of bias) of the individual studies and strength of the body of evidence on the basis of established criteria (18) . The strength of evidence consisted of 4 major categories-high, moderate, low, or insufficient-according to the design, quantity, size, and quality of studies; consistency across studies; precision of estimates; and directness of effect. A second investigator reviewed ratings, and disagreements were resolved by consensus, with a third investigator making the final decision as needed.
Data Synthesis
For most treatments, only single trials were available; data were synthesized qualitatively with attention to such factors as patient characteristics and risk of bias. For treatments with more than 2 trials, the appropriateness of statistical meta-analysis was determined by considering internal validity of the studies and the heterogeneity among studies in design, patient population, interventions, and outcomes. The combined effects were estimated by using a random-effects model based on the profile likelihood method (19) . Combined relative risks were calculated for binary outcomes. For continuous outcomes, the combined weighted mean differences were calculated by using the means and SDs at follow-up from each intervention group. The chisquare test based on the Q statistic and the I 2 statistic (the proportion of variation in study estimates due to heterogeneity) were used to assess heterogeneity in effects between studies, and sensitivity analyses explored statistical heterogeneity when present. All quantitative analyses were performed by using Stata/IC software, version 13.0 (Stata Corp.).
Role of the Funding Source
The AHRQ funded the review, and a working group convened by the NIH helped develop the review's scope and key questions. Neither had a role in study selection, quality assessment, or synthesis. The investigators are solely responsible for the content.
RESULTS
Among the 6175 abstracts identified by searches, 35 treatment trials in 45 publications met inclusion cri- 
Medications
Nine placebo-controlled trials of medications evaluated the effectiveness of rintatolimod (21, 27 ), valganciclovir (28), galantamine (26), hydrocortisone (22) , hydrocortisone plus fludrocortisone (24), IgG (20) , isoprinosine (25), and fluoxetine (23) . None of these medications are FDA approved for CSF. Eight trials met criteria for fair quality (20 -24, 26 -28 ) and 1 for poor quality (25).
Benefits
Rintatolimod, an investigational intravenous immune modulator and antiviral drug, improved measures of exercise performance compared with placebo in 2 fair-quality trials (n = 324) enrolling severely disabled adults (improved cardiopulmonary exercise test tolerance, 36.5% versus 15.2%, P = 0.047; improved exercise duration, 10.3% versus 2.1%, P = 0.007; improved exercise work, 11.8% versus 5.8%, P = 0.01) (low strength of evidence) (21, 27 ). The clinical implications of these changes are unclear. One of these 2 trials also reported improvement in measures of function (activities of daily living and Karnofsky Performance Scale score) (21) , and the other indicated a reduction in use of other medications to relieve CFS symptoms (27). Attrition ranged from 9% to 19% and adherence, from 83% to 91%. In a small, underpowered trial of valganciclovir that enrolled 30 participants with elevated antibody titers who were suspected of having viral-onset ME/CFS, fatigue was improved in the treatment group compared with the placebo group on the basis of 1 scale, but no statistically significant differences were seen for other measures (28). These trials did not report data for patient subgroups.
Trials of galantamine, hydrocortisone, IgG, isoprinosine, and fluoxetine indicated no beneficial effects but were limited by small numbers of participants. Additional trials enrolling fewer than 30 participants and with durations less than 12 weeks indicated no statistically significant differences compared with placebo for acyclovir (57) and showed improved 36-item ShortForm Survey (SF-36) scores for physical health and function with rituximab (58).
Harms
Differences in total withdrawals, withdrawals due to adverse events, and harms of medications were not reported or did not statistically significantly differ between groups for most medications. Participants taking rintatolimod reported flu-like symptoms, chills, vasodilatation, and dyspnea (27). Galantamine was associated with higher rates of withdrawal and attrition than was placebo, demonstrating a dose-dependent relationship; the highest rates were seen at doses of 15 mg or more per day (26). Overall, 90% of participants in the galantamine trial reported harms, with depression, nausea, and headache most common in both the treatment and placebo groups; 2% experienced serious events, although none was attributed to the study drug (26).
In the 2 corticosteroid trials, attrition rates were 10% (22) and 20% (24). Harms that significantly differed between treatment and placebo groups included suppression of adrenal glucocorticoid responsiveness (34% versus 0%; P < 0.001), increased appetite (48% versus 23%; P = 0.02), weight gain (54% versus 23%; P = 0.006), and difficulty sleeping (48% versus 23%; P = 0.02) (22) . Participants taking intravenous IgG (1 g/kg) reported significantly more headaches (93%) than did placebo recipients (60%) (20) . Participants taking fluoxetine had more withdrawals from medicationassociated adverse events compared with the placebo group (13% versus 3%), although total withdrawals did not differ.
Complementary and Alternative Medicines
Seven trials compared complementary and alternative medicine approaches with usual care, placebo, or another intervention (29 -35). Five small trials evaluated dietary approaches or supplements, including a lowsugar/low-yeast diet compared with a healthy diet (29), antioxidant extract of pollen versus placebo (30), acclydine (a supplement proposed to increase biologically active insulin-like growth factor) versus placebo (31), formulations of L-carnitine compared with each other (32), and melatonin versus phototherapy or placebo (35). Additional trials evaluated distant healing (33) and homeopathy (34). One trial met criteria for good quality (31, 33), 5 for fair quality (29, 32, 34, 35), and 1 for poor quality (30).
Benefits
Trials of diets, supplements, or phototherapy indicated no statistically significant differences between treatment and comparison groups. A trial of distant healing that used various techniques of prayer or imagining the transmission of healing energy, light, or power compared with usual care also found no statistically significant differences between groups (33). A trial of homeopathy that used various individualized prescriptions for remedies provided by practitioners versus placebo indicated improved general fatigue for the homeopathy group (Multidimensional Fatigue Inventory, 20-item score, 2.70 versus 1.35; P = 0.04) (34). However, the clinical significance of this small change is not clear, and there were no between-group differences for several other outcomes.
Harms
Patients taking formulations of L-carnitine reported sleeplessness and feeling overstimulated (32). No serious harms were reported in the trial of pollen extract (30).
Counseling and Behavioral Therapies
Fourteen trials in 23 publications evaluated the effectiveness of a counseling or behavioral therapy. Therapies included cognitive behavioral therapy (CBT) intended to change behavioral and belief factors that may trigger and maintain symptoms (36 -38, 40, 43, 44, 48, 59 -61); group or individual counseling wherein participants learned coping and self-sufficiency strategies (8, 45 ); self-instruction through use of informative booklets with assignments (41, 46, 62); pragmatic rehabilitation that provided strategies to promote a gradual progression of activity (40); and supportive listening providing empathic and nondirective support (47, 63, 64) . These therapies were compared with usual care, wait-list control, no treatment, relaxation techniques, adaptive pacing (avoiding activities demanding >70% of a participant's perceived energy), anaerobic therapy that promoted gradual return of pleasurable activities (40, 47, 63, 64), graded exercise therapy (GET) (48), or an alternate form of counseling or behavioral therapy. Five trials met criteria for good quality (44 -48), 6 for fair quality (36 -38, 40, 41, 43), and 3 for poor quality (8, 39, 42) .
Benefits
The effectiveness of counseling and behavior therapies was inconsistent across trials and outcome measures. In some trials, counseling and behavior therapies improved fatigue (8, 38, 39, 41, 43, 46, 48, 62) , physical function ( Figure 1) 
Harms
Three trials reported harms with counseling or behavioral therapies. In the largest trial comparing CBT with adaptive pacing or usual care (PACE [Pacing, graded Activity and Cognitive behaviour therapy: a randomized Evaluation] trial), the therapy group reported significantly fewer serious and nonserious adverse events than the other groups (6% serious events versus 11%; P = 0.03) (48). A trial comparing counseling with a wait-list control group reported no withdrawals due to harms (45), and a trial comparing pragmatic rehabilitation with supportive listening or usual care reported no differences between groups for reported harms or withdrawals due to harms (47).
Exercise Therapies
Seven trials evaluated the effectiveness of exercise therapies. These included GET involving an exercise plan with structured incremental increases in exercise over time (23, 48 , 50, 52, 53), qigong exercise (49, 51), and home orthostatic training (54). Trials compared one form of exercise with another, standard medical care, adaptive pacing, CBT, or placebo. One trial met criteria for good quality (48) and 6 for fair quality (23, 49 -54 (Figure 4) (48, 50, 52); and work impairment (1 trial, n = 475; low to moderate strength of evidence). The largest trial of GET (PACE trial) showed less deterioration of physical function with GET than with control (25% for adaptive pacing versus 18% for usual care versus 11% for GET; P < 0.001), but there were no statistically significant differences in serious deterioration measured by a composite score (48, 65) . No differences between comparison groups were reported in a trial of 314 participants that compared GET with CBT or in a trial of 115 participants that compared CBT plus GET versus usual care (53).
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A trial enrolling 144 participants in China compared qigong exercise with sham qigong (49, 51). Although some measures of fatigue on the Chalder Fatigue Scale were statistically significantly better with the exercise group, others were not. A trial of 38 patients found no statistically significant differences in measures of fatigue between home orthostatic training compared with usual care or sham orthostatic training (54). 
Harms
Harms were poorly reported in exercise trials, and no subgroup analyses were performed. One trial reported small but significantly more serious adverse events (17 exercise versus 7 usual care; P = 0.04) and more nonserious adverse events (992 GET versus 977 usual care versus 949 adaptive pacing versus 848 CBT) in the GET versus comparison groups, although adverse reactions attributed to the intervention were similar between groups (48). In a smaller trial of GET compared with placebo or fluoxetine, total withdrawals were greatest with GET (37% versus 22%) (23) . In addition, in a trial of GET, 20% of patients declined to repeat exercise testing because of perceived harm of testing (52). There were no differences in total withdrawals in the other 2 trials of GET (50, 52), and no harms were reported in other exercise trials (51, 54).
Characteristics of Responders and Nonresponders
Four trials suggested that younger patients with less impairment, who are less focused on symptoms, adherent to cognitive therapy programs, and avoid over-and underexertion (that is, they stay within their energy envelope) are more likely to improve in some measures of fatigue and function (36, 40, 52, 60, 63).
DISCUSSION
Thirty-five trials evaluated the benefits and harms of treatments for adults meeting case definitions primarily for CFS; however, evidence is inconclusive (Appendix Table 2 , available at www.annals.org). Limited evidence indicated that rintatolimod improved measures of exercise performance compared with placebo in severely debilitated participants (low strength of evidence). Counseling, behavior therapies, and GET improved measures of fatigue, function, global improvement, and work impairment; counseling and behavior therapies also improved quality of life (low to moderate strength of evidence). Results of all other interventions and outcomes were from small single trials that provided insufficient strength of evidence. Although adverse effects were rarely reported in most trials, coun- Graded exercise therapy involved an exercise plan with structured incremental increases in exercise over time, qigong exercise, and home orthostatic training. * Compared with all participants in control groups in the trial.
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seling and behavior therapies were associated with fewer harms (low strength of evidence) than medications and GET (insufficient evidence).
These results are consistent with those of previous systematic reviews (66 -70) . A recent systematic review of trials of exercise for patients with CFS found no evidence suggesting that exercise worsens symptoms (70) . However, no trials reported harms for participants meeting case definitions for ME or ME/CSF (48), and it remains unclear how more severely disabled patients respond to exercise therapy. One trial considered participants meeting the London criteria for ME (n = 357 of 640 total) and found similar results for outcomes of fatigue and physical function but did not evaluate harms in this subgroup (48). It is possible that adverse effects of exercise therapy could be avoided by careful selection of patients, and additional research is needed to determine which patients would achieve maximal benefits without incurring harm. Although trials of counseling and behavioral therapies reported mixed results, improvements in multiple outcomes are consistent with outcomes seen with similar therapies for other chronic illnesses (68 -72) .
This systematic review was limited by deficiencies of the trials. Most trials enrolled participants on the basis of case definitions for CFS only. The Oxford CFS case definition is the least restrictive, and its use as entry criteria could have resulted in selection of participants with other fatiguing illnesses or illnesses that resolve spontaneously with time (16, 71) . The Institute of Medicine recently released new diagnostic criteria for CFS that require the presence of postexertional malaise, unrefreshing sleep, and either cognitive impairment or orthostatic intolerance (7, 72) . Participants in previous trials did not meet these requirements. In addition, most treatments were evaluated in single trials designed as pilot studies that enrolled small numbers of participants from specialized clinical centers, and outcomes were assessed by using different methods and outcome measures. Some trials were primarily intended to measure intermediate outcomes, such as natural killer cell-mediated cytotoxicity (25), and most were underpowered for the health outcomes relevant to this systematic review. Although several fatigue and function outcomes were based on validated scales and measures, others were not, and the clinical significance of changes in scores over time is not clear for most of them.
This systematic review included only Englishlanguage trials. No trials analyzed results by relevant subgroups or compared treatment responders with nonresponders. We could not assess publication bias because of the limited number of trials for each intervention. Whereas this review focused on outcomes that are universal to all case definitions of patients, such as fatigue and function, a review of other types of outcomes, such as postexertional malaise, would also be useful.
Future research would benefit from using consistent clinical criteria and comparing outcomes according to clinical presentation, such as postexertional malaise, neurocognitive status, and autonomic dysfunction. This approach would identify patient subgroups that may respond differently to specific treatments and could provide greater insight into the underlying causes of ME/CFS. Studies should report adverse effects more consistently and completely to improve identification of patients who may be negatively affected. Similarly, stratification of results by patient characteristics, such as age, sex, race, baseline functional status, and intermediate outcomes, would help determine the applicability of different treatments for specific patients and situations.
Definitive treatment trials require larger numbers of participants based on appropriate power calculations for clinically relevant outcomes to determine efficacy, along with more rigorous adherence to methodologic standards, such as blinding of outcome assessors, intention-to-treat analysis, and strategies to minimize patient loss to follow-up. Future trials should enroll more men and racial and ethnic minorities; broader age ranges; and participants with greater disability, such as homebound patients. Given the fluctuating nature of ME/CFS, follow-up periods longer than 1 year would help determine effectiveness and harms over time. The development of a set of core outcome measures, including patient-centered outcomes (such as quality of life, employment, and time spent in activity), would help guide research and facilitate future analyses. Trial registries and collaborations would help consolidate and standardize data. Reporting more information about concomitant treatments and adherence to treatment would improve the applicability of study findings. Given the devastating effect of this condition on patients and families, researchers should consider involving the patient and advocate voice in trial planning and development so that future research is relevant and meaningful to those affected by ME/CFS.
In conclusion, trials of rintatolimod, counseling therapies, and GET suggested benefits for patients with CFS, providing low to moderate strength of evidence. However, these treatments have not been adequately tested in broader patient populations, particularly those meeting more specific case definitions. Other treatments and harms have been inadequately studied. More definitive studies are needed to fill these research gaps. 
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